Lofexidine
- TRADE NAMES: BritLofex (Britannia); Lucemyra (US WorldMeds, LLC)
- INDICATIONS: mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults
- CLASS: Adrenergic alpha2-receptor agonist
- HALF-LIFE: ~12 hours
FDA APPROVAL DATE: 05/16/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:PREGNANCY CATEGORY: N/A
The safety of lofexidine in pregnant women has not been established.
Please login to see the rest of this drug profile
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
OTIC.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric